Maintained by Sreepriya Prasannan

MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist

Compiled from ClinicalTrials.gov and CTIS registry records · Last verified 26 Sep 2026 · Editorial standards

At a glance

Peking University is the lead sponsor of 83 current clinical trials in our China register. 43 are recruiting patients now. The most common phase is Not applicable. The drugs named most often in its trials are Camrelizumab, Dalpiciclib and Tislelizumab. The most-studied condition is Esophageal Squamous Cell Carcinoma.

ClinicalTrials.gov trials by status

Recruiting4352%
Not yet open1822%
Active, closed1822%
By invitation45%

Trials by phase

Not applicable4757%
Phase 21316%
Observational1012%
Phase 1810%
Phase EARLY_PHASE134%
Phase 2/311%
Phase 311%

Clinical trials sponsored by Peking University

83 on ClinicalTrials.gov

Study	Phase	Status	Start	Registers
Development and Application of Precision Treatment Strategies for Common Mental Disorders NCT06729541 · ClinicalTrials.gov ↗ · Depression - Major Depressive Disorder, Schizophrenia Disorders, Bipolar Disorder (BD)	Not applicable	Recruiting	2024-11	China
Assessing Iparomlimab and Tuvonralimab in Recurrent or Metastatic MSI-H/dMMR Gastric Cancer NCT07127822 · ClinicalTrials.gov ↗ · Gastric / Gastroesophageal Junction Adenocarcinoma, MSI-H Cancer Drug: Iparomlimab and Tuvonralimab	Phase 2	Recruiting	2025-12	China
Peking University Birth Cohort in Weifang (PKUBC-WF) NCT06234332 · ClinicalTrials.gov ↗ · Health Problems in Pregnancy, Pregnancy Outcomes, Gestational Diabetes	Observational	Recruiting	2024-02	China
Study on the Mechanism of Eating Disorder NCT05862389 · ClinicalTrials.gov ↗ · Anorexia Nervosa, Bulimia Nervosa	Observational	Recruiting	2022-09	China
Study of Dalpiciclib Isethionate Plus Pyrotinib Maleate in the Treatment of Advanced Esophageal Squamous Cell Carcinoma NCT06684600 · ClinicalTrials.gov ↗ · Esophageal Squamous Cell Carcinoma Drugs: Dalpiciclib, Pyrotinib	Phase 2	Recruiting	2024-11	China
FMS-CrossFit Training Program (FCTP) to Improve School Readiness in Preschool Children With Autism Spectrum Disorder NCT07532395 · ClinicalTrials.gov ↗ · Autism Spectrum Disorder	Not applicable	Recruiting	2025-11	China
The Effectiveness of Written Exposure Therapy for PTSD NCT05421494 · ClinicalTrials.gov ↗ · PTSD, Subclinical PTSD	Not applicable	Recruiting	2022-06	China
Linperlisib-based Treatment Regimen in Newly Diagnosed Nodal T-follicular Helper Cell Lymphoma (nTFHL) NCT06347653 · ClinicalTrials.gov ↗ · Nodal T-follicular Helper Cell Lymphoma Drugs: CHOP, Linperlisib	Phase 2	Recruiting	2023-11	China
A Clinical Study on Evaluating Intravenous Administration of IDOV-SAFE NCT06380309 · ClinicalTrials.gov ↗ · Advanced Malignant Solid Tumor of Digestive System	Phase EARLY_PHASE1	Recruiting	2024-05	China
Weekly Dynamics of Psychopathological and Symptom Networks During Mindfulness-Based Interventions for Emotional Distress NCT07280481 · ClinicalTrials.gov ↗ · Depression, Anxiety, Emotional Disorders	Not applicable	Recruiting	2025-11	China
Individualized Exploration of Aerobic Exercise-assisted Treatment of Depression NCT06594588 · ClinicalTrials.gov ↗ · Depression - Major Depressive Disorder	Not applicable	Recruiting	2024-09	China
Phase I Study of OriC902 in Treatment of Advanced HCC NCT06891742 · ClinicalTrials.gov ↗ · HCC	Phase 1	Recruiting	2025-02	China
The STEP-MIED Trial: Digital Stepped-Care for Emotional Disorders NCT07458100 · ClinicalTrials.gov ↗ · Emotional Disorders, Depressive Disorder, Anxiety Disorders	Not applicable	Recruiting	2026-03	China
EVM16 Injection as a Single and Combination With Tislelizumab in Solid Tumors NCT06541639 · ClinicalTrials.gov ↗ · Advanced or Recurrent Solid Tumors Drug: Tislelizumab	Phase 1	Recruiting	2025-03	China
Efficacy and Mechanisms of Escitalopram in Drug-Naïve First-Episode Major Depressive Disorder NCT07480525 · ClinicalTrials.gov ↗ · Depression - Major Depressive Disorder Drug: Escitalopram	Not applicable	Recruiting	2026-03	China
Phase 2 Trial of KN026+KN046±XELOX in HER2-positive Locally Advanced GC NCT06023758 · ClinicalTrials.gov ↗ · HER2-positive Locally Advanced Resectable Gastric Cancer	Phase 2	Recruiting	2023-09	China
Effects of Splinted or Non-splinted Single-unit Crowns on Marginal Bone-level Alterations Around Implants NCT02880891 · ClinicalTrials.gov ↗ · Jaw, Edentulous, Partially	Not applicable	Recruiting	2016-09	China
Immune Checkpoint Inhibitors for Organ Preservation in Non-metastatic dMMR/MSI-H Gastric or Colon Cancers NCT06580574 · ClinicalTrials.gov ↗ · Gastric Cancer, Colon Cancer, MSI-H	Phase 2	Recruiting	2024-09	China
Neoadjuvant Endocrine Therapy Versus Chemotherapy in Premenopausal Patients With ER+ & HER2- Breast Cancer NCT02535221 · ClinicalTrials.gov ↗ · Breast Cancer Drugs: Epirubicin, Goserelin, Ivonescimab	Phase 3	Recruiting	2015-07	China
NKG2D/CLDN18.21 CAR-T(KD-496) in the Treatment of Advanced NKG2DL+/CLDN18.2+ Solid Tumor NCT06134960 · ClinicalTrials.gov ↗ · Gastric Cancer, Pancreatic Cancer, Solid Tumor	Phase 1	Recruiting	2024-11	China
MAGE-A4-directed TCR-T in the Treatment Amongst Subjects With Advanced Solid Tumors NCT06170294 · ClinicalTrials.gov ↗ · Advanced Solid Tumor	Phase 1	Recruiting	2024-01	China
Phase I Clinical Study of YK1101 Injection for the Treatment of Advanced Solid Tumors NCT07139067 · ClinicalTrials.gov ↗ · Advanced Solid Tumor Cancer	Phase 1	Recruiting	2025-04	China
Cardiovascular Risk Assessment and Dynamic Monitoring-based Prevention Trial NCT05919056 · ClinicalTrials.gov ↗ · Cardiovascular Diseases	Not applicable	Recruiting	2023-07	China
Shame-Focused Cognitive Behavioral Therapy For Reducing Suicide Risk In Adolescent Psychiatric Inpatients (SF-CBT) NCT07294001 · ClinicalTrials.gov ↗ · Adolescent Suicide, Suicidal Ideation, Suicidal Behavior	Not applicable	Recruiting	2025-08	China
Trastuzumab Combined With Pyrrolidine and Chemotherapy for Locally HER2 Positive Breast Cancer NCT04481932 · ClinicalTrials.gov ↗ · HER2-positive Breast Cancer	Phase 2	Recruiting	2020-07	China
Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of IPM514 in Patients with Esophageal Squamous Cell Carcinoma NCT06690476 · ClinicalTrials.gov ↗ · Esophageal Squamous Cell Carcinoma Drug: Tislelizumab	Phase EARLY_PHASE1	Recruiting	2024-10	China
The Effectiveness of Group Guided Written Exposure Therapy for CPTSD Symptoms Among Adolescents NCT06931093 · ClinicalTrials.gov ↗ · CPTSD, Compelx Post-traumatic Stress Disorder	Not applicable	Recruiting	2025-04	China
Children to Adults Mental and Psychosomatic Health Study (CAMPS) NCT05621278 · ClinicalTrials.gov ↗ · Mental Health Wellness, Cognitive Function, Physical Symptoms	Observational	Recruiting	2022-09	China
Selective Omission of Axillary Surgery in Triple-negative and HER2-positive Breast Cancer After NACT NCT05314114 · ClinicalTrials.gov ↗ · Breast Cancer Female	Not applicable	Recruiting	2020-07	China
School-Based Intervention to Enhance Resilience and Stress Coping in Rural Chinese Adolescents NCT07115186 · ClinicalTrials.gov ↗ · Stress, Emotional, Stress-related Mental Disorders	Not applicable	Recruiting	2025-05	China
Effectiveness of Digital Cognitive Behavioral Therapy for the Treatment of Depression: a Real-world Study NCT06831435 · ClinicalTrials.gov ↗ · Depression, Bipolar Affective Disorder, Schizophenia Disorder	Not applicable	Recruiting	2024-11	China
Salt Sensitivity Evaluation Via N-of-1 Trials (SENSE-Salt) NCT07614724 · ClinicalTrials.gov ↗ · Salt-Sensitivity of Blood Pressure, Hypertension	Not applicable	Recruiting	2026-06	China
HAIC Plus Systemic Therapy as De-escalation Therapy Strategy for Biliary Tract Cancer NCT07466238 · ClinicalTrials.gov ↗ · Biliary Tract Cancer (BTC) Drugs: Bevacizumab, Gemcitabin	Not applicable	Recruiting	2026-03	China
ctDNA-MRD Monitoring After Resection in Gastric Cancer NCT06893133 · ClinicalTrials.gov ↗ · Gastric Cancer	Observational	Recruiting	2025-04	China
Mindfulness Intervention for Emotional Distress: An EEG Study NCT07692269 · ClinicalTrials.gov ↗ · Emotional Distress, Anxiety, Depression	Not applicable	Recruiting	2026-07	China
The Effects of Time Points to Cease Parenteral Nutrition and IGF-1 on Very Low Birth Weight Infants NCT06071403 · ClinicalTrials.gov ↗ · Growth Retardation	Observational	Recruiting	2023-07	China
3D Facial Scanning for Evaluating Autologous Fat Grafting in Craniofacial Deformities NCT06306326 · ClinicalTrials.gov ↗ · Adipocytes, Autografts, Imaging, Three-Dimensional / Methods	Not applicable	Recruiting	2024-04	China
County Medical Community-based, Cardiovascular Risk Stratified Integrated Care Model: a Pragmatic Cluster Randomised Control Trial NCT06302127 · ClinicalTrials.gov ↗ · Hypertension, Diabetes Mellitus Type 2, Cardiovascular Diseases	Not applicable	Recruiting	2024-05	China
Effectiveness of Cryotherapy Combined With Compression Therapy for Preventing Chemotherapy-induced Peripheral Neuropathy NCT05341141 · ClinicalTrials.gov ↗ · Breast Cancer	Not applicable	Recruiting	2022-06	China
Pregnancy Salt Substitution Trial for Hypertensive Disorders of Pregnancy Prevention (PREG-Salt) NCT07294807 · ClinicalTrials.gov ↗ · Hypertensive Disorders of Pregnancy	Not applicable	Recruiting	2026-01	China
The Effectiveness of Guided Written Exposure Therapy for Complex PTSD in Adolescents NCT07325734 · ClinicalTrials.gov ↗ · CPTSD, Compelx Post-traumatic Stress Disorder	Not applicable	Recruiting	2025-10	China
Sintilimab Combined With IBI310 and Surufatinib for the Treatment of G3-NET and NEC (NESSIE) NCT05165407 · ClinicalTrials.gov ↗ · Neuroendocrine Neoplasm Drugs: Ipilimumab N01, Sintilimab, Surufatinib	Phase 2	Recruiting	2022-07	China
A Cluster-Randomized Trial of a Hypertension Risk Model-Based Precision Intervention in High-Risk Adults in Shunyi District NCT07804420 · ClinicalTrials.gov ↗ · Hypertension	Not applicable	Recruiting	2026-04	China
Child Vaccination Scheduling in China NCT07141875 · ClinicalTrials.gov ↗ · Vaccination Behavior	Observational	Not yet open	2025-08	China
Fangshan Active Nutrition Initiative NCT07519122 · ClinicalTrials.gov ↗ · Childhood Weight Management	Not applicable	Not yet open	2026-09	China
A Prospective, Randomized, Open, Phase II Clinical Study of Chidamide in Combination with Camrelizumab and Apatinib for Advanced Esophageal Cancer NCT06745193 · ClinicalTrials.gov ↗ · Advanced Esophageal Carcinoma	Phase 2	Not yet open	2025-02	China
Targeted TDCS Intervention for Internet Gaming Disorder NCT06759051 · ClinicalTrials.gov ↗ · Internet Gaming Disorder	Not applicable	Not yet open	2024-12	China
A Study of Regorafenib Combined With Envafolimab for Metastatic Gastrointestinal Stromal Tumors With Kit Gene Exon 17 Mutation That Failed Standard Treatment NCT06772233 · ClinicalTrials.gov ↗ · Metastatic Gastrointestinal Stromal Tumors (GIST) Drugs: Envafolimab, Regorafenib	Phase 2	Not yet open	2025-07	China
A Multicenter Real-World Study Evaluating the Efficacy and Safety of Shugan Jieyu Capsules in the Treatment of Depression NCT07785284 · ClinicalTrials.gov ↗ · Outpatients or Inpatients With Depression	Not applicable	Not yet open	2026-09	China
Allogeneic B7H3 CAR-γδT Cell Therapy for Advanced Solid Tumors NCT06825455 · ClinicalTrials.gov ↗ · Advanced Solid Tumors, Ovarian Cancers, Peritoneal (metastatic) Cancer Drugs: Cyclophosphamide, Fludarabine	Phase EARLY_PHASE1	Not yet open	2025-03	China
Effects of Exercise Sequence and Meal Sequence on Weight Management Among Children and Adolescents With Overweight or Obesity: The STEP Trial NCT07712068 · ClinicalTrials.gov ↗ · Obesity & Overweight, Insulin Resistance, Inflamation	Not applicable	Not yet open	2026-07	China
Effect of Food-derived Active Components on Digestive Tract Health in Adults with Irritable Bowel Syndrome NCT06779214 · ClinicalTrials.gov ↗ · Irritable Bowel Syndrome - Diarrhoea	Not applicable	Not yet open	2025-02	China
The Phase I Study of SIG001 Antibody on Cancer Therapy. NCT07486700 · ClinicalTrials.gov ↗ · Neoplams	Phase 1	Not yet open	2026-03	China
Postoperative Adjuvant Therapy for CT041 Gastric or Gastroesophageal Junction (G/GEJ) Adenocarcinoma Patients NCT06857786 · ClinicalTrials.gov ↗ · Gastroesophageal Junction Adenocarcinoma, Gastric Adenocarcinoma	Phase 1	Not yet open	2025-03	China
NW-301 TCR-T in Patients With Advanced Solid Tumor NCT06956261 · ClinicalTrials.gov ↗ · Tumor, Solid Drugs: NW-301D, NW-301V	Phase 1	Not yet open	2025-05	China
AI-Guided Stress Management Breathing Practices Via a Wearable Device NCT06881875 · ClinicalTrials.gov ↗ · Stress Reduction	Not applicable	Not yet open	2025-03	China
A Blood Pressure-Lowering Diet for Preventing and Managing Hypertension NCT07735091 · ClinicalTrials.gov ↗ · Hypertension	Not applicable	Not yet open	2026-08	China
Mechanisms of Mindfulness Intervention: Cognitive Flexibility Dose Manipulation NCT06622122 · ClinicalTrials.gov ↗ · Emotional Distress	Not applicable	Not yet open	2024-10	China
Digital Health Intervention for Early Identification and Prevention of Gestational Diabetes Mellitus NCT07499622 · ClinicalTrials.gov ↗ · Gestational Diabetes Mellitus (GDM)	Not applicable	Not yet open	2026-06	China
A Real-world Study Evaluating the Usage of Camrelizumab in Chinese Patients With Advanced Esophageal Cancer NCT04616040 · ClinicalTrials.gov ↗ · Esophageal Cancer Drug: Camrelizumab	Observational	Not yet open	2020-12	China
AI-GF-GNW on Prolonged Grief Reactions NCT07589088 · ClinicalTrials.gov ↗ · Artificial Intelligence (AI), Prolonged Grief Symptoms, Depression - Major Depressive Disorder	Not applicable	Not yet open	2026-05	China
Smart Analysis and Decision-Making for Emerging Infectious Diseases NCT07678619 · ClinicalTrials.gov ↗ · Emerging Infectious Diseases, COVID-19, Influenza	Not applicable	By invitation	2026-08	China
Adaptive Cognitive Training on Cognitive Function in Elderly Hypertension Patients in the Community NCT06512922 · ClinicalTrials.gov ↗ · Hypertension, Condition, Aging	Not applicable	By invitation	2024-10	China
Multigene Risk Score Combined With Ki-67 Dynamic Assessment in Stratified Neoadjuvant Endocrine Therapy Treatment With or Without CDK4/6 Inhibitors in HR+/HER2- Breast Cancer NCT06650748 · ClinicalTrials.gov ↗ · Breast Cancer, Early-stage Breast Cancer Drugs: Dalpiciclib, Letrozole	Phase 2	By invitation	2025-05	China
Nimotuzumab,Camrelizumab, and Neoadjuvant Chemotherapy（nCT） in the Treatment of Esophageal Squamous Cell Carcinoma NCT07312578 · ClinicalTrials.gov ↗ · Esophageal Squamous Cell Carcinoma Drugs: Albumin paclitaxel, Camrelizumab, Cisplatin	Phase 2	By invitation	2025-11	China
Efficacy of Endoscopy Screening on Esophageal Cancer in China (ESECC) NCT01688908 · Esophageal Squamous Cell Carcinoma, Dysplasia	Not applicable	Active, closed	2012-01	China
Effects of Parent-Adolescent Joint Interventions for Adolescents With Adverse Childhood Experiences NCT06619821 · Stress, Emotional, Stress-related Mental Disorders, Adverse Childhood Experiences	Not applicable	Active, closed	2024-09	China
Paired Emotion Reading Improves Emotion Regulation in Rural Children With ACE NCT06505629 · ClinicalTrials.gov ↗ · Emotion Regulation, Adverse Childhood Experience	Not applicable	Active, closed	2024-07	China
S365: A Multicenter Longitudinal Cohort of Sleep Health NCT06760000 · ClinicalTrials.gov ↗ · Sleep Disorder, Sleep	Observational	Active, closed	2024-08	China
Effect of Perception-based Interventions on Public Acceptance of Using Large Language Models in Medicine NCT07304908 · ClinicalTrials.gov ↗ · Large Language Models, Acceptability of Health Care, Perception, Self	Not applicable	Active, closed	2025-11	China
AK104 in Locally Advanced MSI-H/dMMR Gastric Carcinoma and Colorectal Cancer NCT04556253 · ClinicalTrials.gov ↗ · MSI-H/dMMR Gastric Carcinoma and Colorectal Cancer Drug: Cadonilimab	Phase 2	Active, closed	2024-02	China
Early-Life Strategies for Preventing Obesity in Preschool-aged Children NCT07117149 · ClinicalTrials.gov ↗ · Childhood Obesity Prevention	Not applicable	Active, closed	2025-10	China
Compare Neoadjuvant DOS Combined With Toripalimab Versus SOX Combined With Toripalimab in Locally Advanced Gastric Adenocarcinoma NCT03691454 · ClinicalTrials.gov ↗ · Gastric Adenocarcinoma Drugs: Docetaxel, Oxaliplatin, Tegafur Gimeracil Oteracil	Phase 2/3	Active, closed	2018-06	China
HAIC Plus Lenva and PD-1 for Advanced HCC With Macrovascular or Biliary Invasion NCT07466225 · ClinicalTrials.gov ↗ · Hepatocellular Carcinoma (HCC) Drug: Lenvatinib	Observational	Active, closed	2026-05	China
AI Chatbots for Anxiety Mental Health Literacy NCT07316374 · ClinicalTrials.gov ↗ · Anxiety Literacy, Anxiety Disorders, Mental Health Literacy	Not applicable	Active, closed	2025-12	China
Testing the Effectiveness of AI Chatbots to Improve Public Knowledge and Attitudes Towards Depression NCT06858371 · ClinicalTrials.gov ↗ · Depression Literacy, Depression Disorders, Stigma of Mental Illness	Not applicable	Active, closed	2025-02	China
EXpress Prevent Rural oldEr Adults' fallS, fractureS and Dependency (EXPRESS) NCT06984978 · ClinicalTrials.gov ↗ · Falls, Falls Injury, Fall Prevention	Not applicable	Active, closed	2024-08	China
Pembrolizumab and Chemotherapy Neoadjuvant/Adjuvant of NSCLC NCT05894889 · ClinicalTrials.gov ↗ · Stage IIIB(N2) Non-small Cell Lung Cancer, Stage IIA Non-small Cell Lung Cancer, Stage IIB Non-small Cell Lung Cancer Drugs: Carboplatin, Nab-paclitaxel, Pembrolizumab	Phase 2	Active, closed	2024-01	China
Long COVID and Its Associations With Health Outcomes in Older Adults NCT05825651 · ClinicalTrials.gov ↗ · Long COVID, COVID-19 Pandemic, Elderly Infection	Observational	Active, closed	2023-04	China
Effects of Parent-Adolescent Joint I-Interventions for Adolescents with Adverse Childhood Experiences NCT06650696 · ClinicalTrials.gov ↗ · Stress-related Problem, Stress, Emotional	Not applicable	Active, closed	2024-09	China
Targeted Agent Evaluation in Digestive Cancers in China Based on Molecular Characteristics NCT04584008 · ClinicalTrials.gov ↗ · Biliary Tract Neoplasms, Gastric Cancer, Esophageal Squamous Cell Carcinoma	Not applicable	Active, closed	2020-09	China
Effects of Digital Health Interventions on the Physical and Mental Health of Middle School Students NCT06547567 · ClinicalTrials.gov ↗ · Pediatric Obesity	Not applicable	Active, closed	2026-05	China
Obesity Prevention in School-aged Children NCT07203300 · ClinicalTrials.gov ↗ · Childhood Obesity Prevention	Not applicable	Active, closed	2025-10	China

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.

Drugs in Peking University trials

36 compounds

Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.

Conditions in Peking University trials

126 conditions

Esophageal Squamous Cell Carcinoma5 Hypertension5 Depression - Major Depressive Disorder4 Gastric Cancer4Stress, Emotional3Breast Cancer3Stress-related Mental Disorders2Childhood Obesity Prevention2Emotional Disorders2Gastric Adenocarcinoma2 Anxiety Disorders2 Cardiovascular Diseases2CPTSD, Compelx Post-traumatic Stress Disorder2Depression2Emotional Distress2Anxiety2Dysplasia1Adverse Childhood Experiences1Schizophrenia Disorders1Bipolar Disorder (BD)1Gastric / Gastroesophageal Junction Adenocarcinoma1MSI-H Cancer1Vaccination Behavior1Childhood Weight Management1

By trial register

Register	Trials	Recruiting
Clinical trials in China	83	43

A trial with sites in more than one country appears in each of those registers.

Other sponsors in Esophageal Squamous Cell Carcinoma

Sponsor	Trials
Hebei Medical University Fourth Hospital	4
Tang-Du Hospital	4
Shanghai Zhongshan Hospital	4
Anhui Provincial Hospital	4
Zhejiang Cancer Hospital	3
Fujian Medical University Union Hospital	3
Sichuan Cancer Hospital and Research Institute	2
Karolinska University Hospital	1
Shandong Boan Biotechnology	1
Affiliated Cancer Hospital of Shantou University Medical College	1

Sponsors with the most current trials registered for this condition.

Questions about Peking University trials

How many clinical trials does Peking University sponsor?

Peking University is the lead sponsor of 83 current trials on ClinicalTrials.gov in our China register, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.

Are Peking University trials recruiting?

Yes. 43 of its 83 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Which drugs is Peking University testing?

Its current trials name 36 drugs and biologicals as interventions. The most frequent are Camrelizumab (2), Dalpiciclib (2), Tislelizumab (2), Albumin paclitaxel (1) and Bevacizumab (1). The number in brackets is how many of its trials name each drug.

Where does this information come from?

Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.

How this page is built

Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.

ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, lead sponsor, phase, overall status, start date, conditions and intervention names
EU Clinical Trials Information System (CTIS) ↗ EU trial numbers, titles, sponsor, phase, status, therapeutic area and member-state countries

This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 26 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.

Peking University clinical trials